Announcements Trials
Browse Landscape

Status

Completed 208Recruiting 110Unknown 71Active not recruiting 52Terminated 46Withdrawn 19Not yet recruiting 14No longer available 4Enrolling by invitation 4Approved for marketing 2Suspended 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Recurrence 11Carcinoma, Non-Small-Cell Lung 11Neoplasms 8Prostatic Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Leukemia, Myeloid, Acute 4Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lambert-Eaton Myasthenic Syndrome 3HER2-positive Breast Cancer 3Glioma 3Carcinoma, Medullary 3Thyroid Neoplasms 2Stomach Neoplasms 2Pheochromocytoma 2Paraganglioma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Myasthenic Syndromes, Congenital 2Lymphoma 2Liver Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Head and Neck Neoplasms 2

Interventions

lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × Neuroendocrine Tumors × Clear all
NCT04334837 2020-10-09

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Curium US LLC

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

NCT02705313 2018-04-09

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Advanced Accelerator Applications

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡